dss

Dextran sulfate sodium salt (MW 4500-5500) is a polymer of dehydrated glucose and an inhibitor of complement and coagulation pathways. Dextran sulfate sodium salt (MW 4500-5500) can be used as an anticoagulant, antiviral agent and antilipidemic agent. Dextran sulfate sodium salt (MW 4500-5500) can prevent the HIV-1 virus from adsorbing onto host cells. Dextran sulfate sodium salt (MW 4500-5500) can inhibit NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 4500-5500) can inhibit the immediate blood-mediated inflammatory response (IBMIR).

Dextran sulfate sodium salt (MW 36,000–50,000) is a medium molecular weight polyanionic dextran derivative with strong intestinal epithelial permeability. It is the most commonly used agent for inducing inflammatory bowel disease (IBD) models, effectively inducing both acute and chronic colitis. Its mechanism may involve macrophage dysfunction and gut microbiota dysbiosis. Due to its colonic epithelial toxicity, long-term use can also induce colorectal cancer models.

1. Norisoboldine ((+)-Laurelliptine) might be a potential therapeutic agent for rheumatoid arthritis, and it functions through protecting joint destruction as well as regulating the abnormal immune responses. 2. Norisoboldine inhibits the macrophage activation and the resultant production of pro-inflammatory cytokines via down-regulating the activation of MAPKs signaling pathways rather than NF-κB.

DSS Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It is a homobifunctional crosslinker that is cell membrane permeable, with amine-reactive NHS esters at both ends of an 8-atom [11.4 angstrom] spacer arm for conjugating proteins, including intracellular proteins.

DSS-d4 Deuterated Crosslinker, or Bis[Succinimidyl] 2,2,7,7-suberate-d4 is a membrane permeable crosslinker with four deuterium atoms.

DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.

DSSeb Crosslinker (Disuccinimidyl sebacate) is a dual N-hydroxyethyl ketone ester and cell-membrane-permeable amine-reactive crosslinker, suitable for protein crosslinking and investigating protein-protein interactions.

PTDSS1-IN-1 is an active molecule that can be used in life science related research. The CAS number of PTDSS1-IN-1 is 2488609-21-6.

SDSSD is a peptide that targets osteoblasts by selectively binding to them through periostin. Nanomaterials modified with SDSSD can be utilized in the study of osteoblast-induced bone diseases.

Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

NLRP3-IN-48 is an inhibitor of NLRP3. It suppresses the activation of the NLRP3 inflammasome by targeting the NLRP3 protein, thereby interfering with the assembly of the NLRP3 inflammasome. Additionally, NLRP3-IN-48 exhibits anti-inflammatory activity in a DSS-induced acute colitis model in mice.

FKK6 is a selective agonist of the pregnane X receptor (PXR) with an EC50 of 1.2 µM. It demonstrates strong affinity for plasma proteins and exhibits favorable metabolic characteristics in human microsomes. FKK6 inhibits the PXR-related NF-κB signaling pathway, reducing the expression of inflammatory factors and showing anti-inflammatory activity in a mouse model of DSS-induced colitis.

CB2 receptor agonist 9 (Compound 33) is an orally active agonist of cannabinoid receptor 2 (CB2 receptor) with an EC50 of 16.2 nM. It inhibits the expression of TNF-α, IL-1β, and IL-6, demonstrating anti-inflammatory activity in a DSS-induced acute colitis model in mice.

RIPK2/3 inhibitor 29 (compound 29) is a dual inhibitor of RIPK2 (IC50=12 nM) and RIPK3 (IC50=18 nM), which can directly bind to RIPK2 and RIPK3, effectively inhibiting NOD induced cytokine production and cell necrosis. Compound 29 has shown significant therapeutic effects in DSS induced colitis mouse models and has broad potential for dual inhibition of RIPK2/RIPK3 in the treatment of IBD.

EP4 receptor agonist 3 is an activator of the EP4 receptor and is useful for research in the DSS-induced colitis mouse model.

ISM012-042 is an orally active inhibitor of PHD1 and PHD2, with IC50 values of 1.9 and 2.5 nM, respectively. At a concentration of 2.5 μM, ISM012-042 protects Caco-2 cells from DSS-induced barrier damage. Additionally, in LPS-induced bone marrow-derived dendritic cells (BMDC) from mice, ISM012-042 exhibits anti-inflammatory properties by dose-dependently reducing the expression of IL-12 subunit IL-12p35 and TNF. It also restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 is useful for studying intestinal mucosal repair and immune disorders.

Keap1-Nrf2-IN-25 (Compound 19) is a potent Keap1-Nrf2 inhibitor with an IC50 of 0.55 μM and exhibits a Keap1 binding affinity (Kd of 0.50 μM). This compound activates Nrf2, reducing reactive oxygen species (ROS) and pro-inflammatory cytokines (IL-1β, IL-6). Additionally, Keap1-Nrf2-IN-25 provides protective effects against DSS-induced colitis.

GHN105 is an orally active STING inhibitor that suppresses STING-dependent IFN-β secretion in THP-1 human monocytes with an IC50 of 4.4 μM. In mice, GHN105 reduces serum levels of IFN-β, IL-6, and CXCL10, and alleviates colitis in a DSS-induced acute colitis mouse model. Additionally, GHN105 demonstrates favorable pharmacokinetic properties in mice, with an oral bioavailability of 43% and a half-life of 1.1 hours.

5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory properties. It suppresses IL-6, IL-1β, TNF-α, and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. Additionally, 5-LOX-IN-8 decreases the disease activity index in DSS colitis models. This compound is applicable for research in inflammatory bowel disease (IBD).

Quin-C7 is an orally active FPR2/ALX antagonist with anti-inflammatory properties. It demonstrates efficacy in ameliorating DSS-induced colitis in mice and is suitable for research in inflammatory bowel disease [IBD].

Anti-inflammatory agent 97 (Compound 1l) is an anti-inflammatory compound and also inhibits oxidative stress. It can reduce colon shortening and alleviate inflammatory symptoms in a mouse model of ulcerative colitis induced by DSS. Additionally, it modulates the inflammation-associated TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway.

NLRP3-IN-76 is an orally active NLRP3 inhibitor that suppresses the production of NO and reduces the mRNA levels of pro-inflammatory cytokines (iNOS, IL-6, IL-1β, and TNFα). It exerts anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and the NF-κB signaling pathway. Furthermore, NLRP3-IN-76 can ameliorate DSS-induced colitis and is applicable for studying inflammatory bowel disease (IBD).

Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory properties. It inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice.